Published 9 days ago • loading... • Updated 3 days ago

Sanofi Accelerates Chlamydia Prevention with Fast Tracked mRNA Vaccine

Summary by EuropaWire.eu

Sanofi Accelerates Chlamydia Prevention with Fast Tracked mRNA Vaccine (IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue. Designed to protect against primary and recurrent infections caused by Chlamydia trachomatis, the vaccine is set to undergo a phase 1/2 clinical trial in adults aged 18 to 29, with the …

Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.

7 Articles

All

Left

Center

Right

WLTReport

Far Right

FDA Fast-Tracks mRNA Vaccine Candidate

The U.S. Food and Drug Administration (FDA) has fast-tracked an mRNA vaccine candidate for chlamydia. “The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need,” a press release from Sanofi read. “The chlamydia vaccine ca…

3 days ago

Read Full Article

Pharmaphorum

FDA fast-tracks Sanofi's experimental chlamydia vaccine

Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.

8 days ago

Read Full Article

GeneOnline News

Sanofi Secures FDA Fast Track Designation for its Chlamydia Prevention mRNA Vaccine

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Sanofi's mRNA vaccine candidate for chlamydia prevention.

8 days ago

Read Full Article

The Srpska Times

Serbian biotech Dren Bio sold to Sanofi for $1.9bn

Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on March 20. This acquisition is a major milestone for the Serbian biotech sector and highlights the growing international recognition of innovations emerging from the region. The agreement sees Sanofi acquire Dren Bio’s autoimmune disease […] The post Serbian biotech Dren Bio sold to Sanofi for .9bn fi…

9 days ago

Read Full Article

intelligenthq.com

Emerging Concerns Surrounding mRNA Technology Advancements

Recent developments in mRNA technology have raised significant concerns among scientists and health experts. As the technology continues to evolve, questions about its long-term effects and ethical implications are becoming increasingly prominent. This article explores the latest findings and the potential ramifications for public health and biotechnology. Key Takeaways mRNA technology is advancing rapidly, with applications beyond vaccines. Co…

9 days ago

Read Full Article